A recombinant human ACE2 (APN01) was found to decrease the levels of angiotensin II and plasma IL-6 in different patients diagnosed with ARDS (acute respiratory distress syndrome) may also be utilized for inhibiting SARS-CoV-2 from accessing cellular ACE2 receptor (Zhang et al., 2020a). This evidence concerns the gene IL6 and acute respiratory distress syndrome.